Jonathan P Jarow1, Seth P Lerner2, Paul G Kluetz3, Ke Liu4, Rajeshwari Sridhara5, Dean Bajorin6, Sam Chang7, Colin P N Dinney8, Susan Groshen9, Ronald A Morton10, Michael O'Donnell11, Diane Zipursky Quale12, Mark Schoenberg13, John Seigne14, Bhadrasain Vikram15. 1. Office of Hematology and Oncology Products, Food and Drug Administration, Silver Spring, MD. Electronic address: Jonathan.jarow@fda.hhs.gov. 2. Scott Department of Urology, Baylor College of Medicine Medical Center, Houston, TX. 3. Office of Hematology and Oncology Products, Food and Drug Administration, Silver Spring, MD. 4. Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD. 5. Division of Biometrics V, Office of Biostatistics, CDER, Food and Drug Administration, Silver Spring, MD. 6. Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY. 7. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN. 8. The University of Texas MD Anderson Cancer Center, Houston, TX. 9. Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, USC/Keck School of Medicine, Los Angeles, CA. 10. American Medical Systems, Minnetonka, MN. 11. University of Iowa, Iowa city, IA. 12. Bladder Cancer Advocacy Network, Bethesda, MD. 13. Johns Hopkins University School of Medicine, Baltimore, MD. 14. Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH. 15. National Cancer Institute, Bethesda, MD.
Abstract
OBJECTIVE: To summarize the discussion at a public workshop, cosponsored by the U.S. Food and Drug Administration (FDA) and the American Urological Association, reviewing potential trial designs for the development of new therapies for non-muscle-invasive bladder cancer (NMIBC). There have been only 3 drug approvals for NMIBC in the last 30 years, and product development for this disease has been stymied by difficulties in trial design and patient accrual. METHODS: A workshop evaluating potential trial design for the development of therapies for NMIBC was held in San Diego, CA, in May 2013. Invited experts representing all stakeholders, including urology, medical oncology, radiation oncology, industry, and patient advocates, discussed development of products for all risk strata of NMIBC. RESULTS: The panel responded to specific questions from the FDA, discussing eligibility criteria, efficacy endpoints, and trial design for patients with a mix of high-grade papillary disease and carcinoma in situ, Bacillus Calmette-Guerin (BCG)-refractory disease, and intermediate-risk disease. Panel members also addressed the magnitude of response that would be clinically meaningful for various disease strata and trial design options for perioperative intravesical chemotherapy instillation at the time of resection of bladder tumors. CONCLUSION: Expert commentary provided by panel members will inform a planned FDA guidance on pathways for drug and biologic development for NMIBC and will be discussed at meetings of the FDA's Oncologic Drugs Advisory Committee. FDA intends to develop a set of principles that can be used to promote the development of new products for this disease. Published by Elsevier Inc.
OBJECTIVE: To summarize the discussion at a public workshop, cosponsored by the U.S. Food and Drug Administration (FDA) and the American Urological Association, reviewing potential trial designs for the development of new therapies for non-muscle-invasive bladder cancer (NMIBC). There have been only 3 drug approvals for NMIBC in the last 30 years, and product development for this disease has been stymied by difficulties in trial design and patient accrual. METHODS: A workshop evaluating potential trial design for the development of therapies for NMIBC was held in San Diego, CA, in May 2013. Invited experts representing all stakeholders, including urology, medical oncology, radiation oncology, industry, and patient advocates, discussed development of products for all risk strata of NMIBC. RESULTS: The panel responded to specific questions from the FDA, discussing eligibility criteria, efficacy endpoints, and trial design for patients with a mix of high-grade papillary disease and carcinoma in situ, Bacillus Calmette-Guerin (BCG)-refractory disease, and intermediate-risk disease. Panel members also addressed the magnitude of response that would be clinically meaningful for various disease strata and trial design options for perioperative intravesical chemotherapy instillation at the time of resection of bladder tumors. CONCLUSION: Expert commentary provided by panel members will inform a planned FDA guidance on pathways for drug and biologic development for NMIBC and will be discussed at meetings of the FDA's Oncologic Drugs Advisory Committee. FDA intends to develop a set of principles that can be used to promote the development of new products for this disease. Published by Elsevier Inc.
Authors: Jean V Joseph; Ralph Brasacchio; Chunkit Fung; Jay Reeder; Kevin Bylund; Deepak Sahasrabudhe; Shu Yuan Yeh; Ahmed Ghazi; Patrick Fultz; Deborah Rubens; Guan Wu; Eric Singer; Edward Schwarz; Supriya Mohile; James Mohler; Dan Theodorescu; Yi Fen Lee; Paul Okunieff; David McConkey; Hani Rashid; Chawnshang Chang; Yves Fradet; Khurshid Guru; Janet Kukreja; Gerald Sufrin; Yair Lotan; Howard Bailey; Katia Noyes; Seymour Schwartz; Kathy Rideout; Gennady Bratslavsky; Steven C Campbell; Ithaar Derweesh; Per-Anders Abrahamsson; Mark Soloway; Leonard Gomella; Dragan Golijanin; Robert Svatek; Thomas Frye; Seth Lerner; Ganesh Palapattu; George Wilding; Michael Droller; Donald Trump Journal: Bladder Cancer Date: 2018-10-03
Authors: Neal D Shore; Stephen A Boorjian; Daniel J Canter; Kenneth Ogan; Lawrence I Karsh; Tracy M Downs; Leonard G Gomella; Ashish M Kamat; Yair Lotan; Robert S Svatek; Trinity J Bivalacqua; Robert L Grubb; Tracey L Krupski; Seth P Lerner; Michael E Woods; Brant A Inman; Matthew I Milowsky; Alan Boyd; F Peter Treasure; Gillian Gregory; David G Sawutz; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney Journal: J Clin Oncol Date: 2017-08-23 Impact factor: 44.544
Authors: Roger Li; Debasish Sundi; Jingsong Zhang; Youngchul Kim; Richard J Sylvester; Philippe E Spiess; Michael A Poch; Wade J Sexton; Peter C Black; James M McKiernan; Gary D Steinberg; Ashish M Kamat; Scott M Gilbert Journal: Eur Urol Date: 2020-03-04 Impact factor: 20.096
Authors: Ashish M Kamat; Richard J Sylvester; Andreas Böhle; Joan Palou; Donald L Lamm; Maurizio Brausi; Mark Soloway; Raj Persad; Roger Buckley; Marc Colombel; J Alfred Witjes Journal: J Clin Oncol Date: 2016-01-25 Impact factor: 44.544
Authors: Stephen A Boorjian; Mehrdad Alemozaffar; Badrinath R Konety; Neal D Shore; Leonard G Gomella; Ashish M Kamat; Trinity J Bivalacqua; Jeffrey S Montgomery; Seth P Lerner; Joseph E Busby; Michael Poch; Paul L Crispen; Gary D Steinberg; Anne K Schuckman; Tracy M Downs; Robert S Svatek; Joseph Mashni; Brian R Lane; Thomas J Guzzo; Gennady Bratslavsky; Lawrence I Karsh; Michael E Woods; Gordon Brown; Daniel Canter; Adam Luchey; Yair Lotan; Tracey Krupski; Brant A Inman; Michael B Williams; Michael S Cookson; Kirk A Keegan; Gerald L Andriole; Alexander I Sankin; Alan Boyd; Michael A O'Donnell; David Sawutz; Richard Philipson; Ruth Coll; Vikram M Narayan; F Peter Treasure; Seppo Yla-Herttuala; Nigel R Parker; Colin P N Dinney Journal: Lancet Oncol Date: 2020-11-27 Impact factor: 41.316